¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"ȯ"¿¡ ´ëÇÑ ´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ÀÇÇпë¾î ¼¼ºÎ °Ë»ö °á°úÀÔ´Ï´Ù
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • psychedelic drug
    ȯ°¢Á¦(ü³ÊÆð¥)
  • reduced substrate concentration
    ȯ»ê ±âÁú ³óµµ(üµß©Ñ¨òõÒØÓø)
  • reduced scattered light intensity
    ȯ»ê »ê¶õ±¤ °­µµ(üµß©ß¤Õ¯ÎÃË­Óø)
  • reduced osmotic pressure
    ȯ»ê »ïÅõ¾Ð(üµß©ß¶÷âäâ)
  • reduced viscosity
    ȯ»ê Á¡µµ(üµß©ïÄÓø)
  • reduced mean residue rotation
    ȯ»ê Æò±Õ Àܱâ ȸÀü(üµß©øÁгíÑÐñüÞï®)
  • toroidal supercoil
    ȯ»ó(ü»ßÒ)¼öÆÛÄÚÀÏ
  • annulation reaction
    ȯ»óÇü¼º ¹ÝÀÀ(ü»ßÒû¡à÷Úãëë)
  • reducing equivalent
    ȯ¿ø ´ç·®(ü½êªÓ×Õá)
  • reducing agent
    ȯ¿ø ½Ã¾à(ü½êªãËå·)
  • reduction potential
    ȯ¿ø ÀüÀ§(ü½êªï³êÈ)
  • reduction phase
    ȯ¿ø±â(ü½êªÑ¢)
  • reducing sugar
    ȯ¿ø´ç(ü½êªÓØ)
  • reducing power
    ȯ¿ø·Â(ü½êªÕô)
  • reducing atmosphere
    ȯ¿ø¼º ´ë±â(ü½êªàõÓÞѨ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 1
  • ¿µ¹®
    ÇѱÛ
  • acetate-replacing factor
    ¾Æ¼¼Æ®»ê(ß«)ġȯ ÀÎÀÚ(öÇüµì×í­)
  • alkali disease
    ¾ËÄ®¸®¼ºÁúȯ(òðü´)
  • allogeneic disease
    µ¿Á¾ÀÌÀÎÀÚÇü Áúȯ(ÔÒðúì¶ì×í­úþ òðü´)
  • amino acid substitution
    ¾Æ¹Ì³ë»ê ġȯ(öÇüµ)
  • anion exchanger
    À½(ëä)À̿ ±³È¯Á¦(Îßüµð¥)
  • antigenic conversion
    Ç׿øÀüȯ(ù÷ê«ï®üµ)
  • assimilatory reduction
    µ¿È­Àûȯ¿ø (ÔÒûùîÜü½êª)
  • autoallergic disease
    ÀÚ°¡(í»Ê«)¾Ë·¹¸£±â Áúȯ(òðü´)
  • autoimmune disease
    ÀÚ°¡¸é¿ªÁúȯ (í»Ê«Øóæ¹òðü´)
  • Balbiani ring
    ¹ßºñ¾Æ´Ï ȯ(ü»)
  • base-pair substitution
    ¿°±â¦ ġȯ(öÇüµ)
  • base substitution
    ¿°±âġȯ(ç¤ÐñöÇüµ)
  • biological oxidation-reduction
    »ýü »êȭȯ¿ø(ßæô÷ß«ûùü½êª)
  • biotope
    »ýüȯ°æ(ßæô÷ü»ÌÑ)
  • biotransformation
    »ýüº¯È¯(ßæô÷ܨüµ)
ÅëÇÕ°Ë»ö ¿Ï·á